Heartseed Raises $37 Million in Series C Funding to Accelerate Development of iPSC-Derived Stem Cell Therapy for Heart Failure

Heartseed, Inc., a biotechnology company developing iPSC-derived cardiomyocytes for heart failure, announced it has raised approx. $37 Million at Series C round. These funds will accelerate the initiation of a global clinical trial of HS-001, an allogeneic iPSC-derived, highly purified ventricular cardiomyocyte spheroids for heart failure.